Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty ...

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

We recently compiled a list of the 10 Hottest Mid-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...

Insights into the digital tools that can help improve patient engagement and advance understanding in deep vein thrombosis ...

This page features the latest news about the Inari Med stock. Inari medical director William Hoffman sells $12.1 million in stock William Hoffman, a director at Inari Medical (TASE:PMCN), Inc ...

Inari’s portfolio of medical devices and accessories to treat venous thromboembolism (VTE), or blood clots in the veins, was highly attractive to Stryker, according to Inari Chief Executive Drew Hykes ...

Inari Medical Inc. (NASDAQ ... and other venous diseases through clot removal without the use of thrombolytic drugs. Each year, VTE impacts nearly one million lives in the United States, mostly ...

Inari Medical Inc. (NASDAQ:NARI) is expected to enhance Stryker’s portfolio by expanding its treatment options for venous thromboembolism (VTE), a condition characterized by blood-vein clotting, and ...

Inari Medical, Inc builds minimally invasive ... capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large ...